Sava Infond D.O.O. Alnylam Pharmaceuticals, Inc. Transaction History
Sava Infond D.O.O.
- $640 Billion
- Q2 2025
A detailed history of Sava Infond D.O.O. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Sava Infond D.O.O. holds 2,180 shares of ALNY stock, worth $948,518. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,180
Previous 2,080
4.81%
Holding current value
$948,518
Previous $562 Million
26.57%
% of portfolio
0.11%
Previous 0.11%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
746Shares Held
110MCall Options Held
966KPut Options Held
841K-
Capital World Investors Los Angeles, CA16.7MShares$7.29 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$5.68 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.15 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$3.11 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.92 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $53.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...